Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue i...
Company to host conference call at 8:00 AM ET
SOUTH SAN FRANCISCO, Calif.: Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, before the opening of the market on Friday, August 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com.
The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
Fonte: Business Wire
Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…
Eni's VC company invest in the Italian drone company to develop new solutions for industrial plants monitoring
Oracle recognizes Technology Reply’s ability to develop and deliver pioneering solutions through partnering with Oracle
Scheduled for October, the world's largest startup event will bring together more than 2,000 exhibitors in Dubai, UAE
Jenzabar, Inc., a leading technology innovator in higher education, today announced that Jenzabar One was named a Leader in the IDC MarketScape: North…
2024 AUDIT & BEYOND CONFERENCE — AuditBoard, the leading cloud-based platform transforming audit, risk, compliance, and ESG management, wrapped up…
TechCrunch Disrupt 2024 will feature cutting-edge technology from 24 tech startups from South Korea. The Korea Pavilion is presented by Korea Trade-Investment…
In response to the growing demand for AI skills in the workforce, University of Phoenix is excited to announce the launch of new career-focused skill…